2-[4-(N-Benzyloxycarbonyl)Amino-1,3-Dihydro-1-Oxo-2H-Isoindol-2-Yl]Glutaramide置于5% Pd(II)/c(Eggshell) N,N-二甲基甲酰胺体系中,用 N,N-二甲基甲酰胺,甲醇 用作溶剂,化学反应 2.0H,以72%的收率获得来那度胺 参考文献: Methods For Synthesizing 3-(Substituted Dihydroisoindolinone-2-yl)-2,6-Dioxopiperidine,And Intermediates Thereof[fr] Procédés Pour La Synthèse De 3-[(Dihydroisoindolinone Substituée)-2-Yl]-2,6-Dioxopipéridine Et Intermédiaires Correspondants 标题: Methods For Synthesizing 3-(Substituted Dihydroisoindolinone-2-yl)-2,6-Dioxopiperidine,And Intermediates Thereof[fr] Procédés Pour La Synthèse De 3-[(Dihydroisoindolinone Substituée)-2-Yl]-2,6-Dioxopipéridine Et Intermédiaires Correspondants 摘要:本发明揭示了合成3-(取代二氢异吲哚酮-2-基)-2,6-二氧代哌啶及其中间体的方法,即合成式(I)化合物的方法,其中每个取代基固定在专利规范中定义.由于高生产率,对环境影响小和材料易得的优点,本发明的方法适用于工业生产.
专利号:US-2015182634-A1 优先权日:2012-12-28 标 题:Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action 发明人:COYNE CODY P; BEAR RYAN; JONES TONI 权利人:COYNE CODY P; BEAR RYAN; JONES TONI 摘要:Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs. Examples of pharmaceutical-ligand preparations that can be synthesized utilizing the multi-step chemical reaction schemes include covalent chemotherapeutic-ligand agents that possess selective targeted delivery properties and a capacity to exert additive and synergistic levels of cytotoxic anti-neoplastic potency. Pharmaceutical-pharmaceutical analogs, including chemotherapeutic-chemotherapeutic analogs that are capable of exerting multiple mechanisms of action, can be synthesized using either of the described multi-phase or single-phase organic chemistry reaction schemes. Each of these representative examples has utility against a spectrum of disease states including, for example, neoplastic conditions such as mammary adenocarcinoma/carcinoma, ovarian carcinoma, prostatic carcinoma, intestinal carcinoma, melanoma, leukemia, myeloma, and lymphoma.
专利号:US-10973847-B2 优先权日:2017-06-30 标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof 发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
专利号:US-2024209029-A1 优先权日:2021-04-21 标题:Adiponectin glycopeptides and compositions and methods of use thereof 发明人:WANG YU; LI XUECHEN; XU AIMIN; WU HONGXIANG; ZHANG YIWEI; LI YUANXIN 权利人:UNIV HONG KONG 摘要:An improved method for the chemical synthesis of glycosylated peptides has been developed. The method uses stereoselective glycan synthesis and chemical peptide ligation to produce glycopeptides at lower-cost and with higher efficiency/yield compared to conventional methods. In particular, a method for the large-scale, chemical synthesis of hydroxylated amino acid building blocks and glycosylated amino acids suitable for solid phase peptide synthesis (SPPS) are disclosed. SPPS-based methods using the glycosylated amino acids to chemically synthesize adiponectin-like peptides are also described. In vivo studies show that the adiponectin mimicking glycopeptides exhibit significant anticancer, anti-obesity and insulin sensitizing effects. Pharmaceutical compositions of the synthetic glycopeptides and methods of use thereof in treating diseases associated with deficient adiponectin are also described.
专利号:US-6765089-B1 优先权日:1997-09-24 标 题 :Protecting and linking groups for organic synthesis on solid supports 发明人:TOTH ISTVAN; DEKANY GYULA; KELLAM BARRY 权利人:ALCHEMIA PTY LTD 摘要:This invention relates to methods for synthesis of organic compounds, and in particular to compounds useful as protecting and linking groups for use in the synthesis of peptides, oligosaccharides, glycopeptides and glycolipids. The invention provides protecting and linking groups that are useful in both solid phase and solution synthesis, and are particularly applicable to combinatorial synthesis.
专利号:US-2021220331-A1 优先权日:2016-05-03 标题:Inhibitors of ires-mediated protein synthesis 发明人:GERA JOSEPH F; LICHTENSTEIN ALAN; JUNG MICHAEL E; LEE JIHYE; HOLMES BRENT; BENAVIDES-SERRATO ANGELICA 权利人:UNIV CALIFORNIA; THE UNITED STATE GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS 摘要:This disclosure relates to inhibitors of IRES-mediated protein synthesis, compositions comprising therapeutically effective amounts of these compounds, and methods of using those compounds and compositions in treating hyperproliferative disorders, e.g., cancers. This disclosure also relates to compositions comprising inhibitors of IRES-mediated protein synthesis and mTOR inhibitors, and to methods of treating cancer by conjoint administration of inhibitors of IRES-mediated protein synthesis and mTOR inhibitors.
专利号:US-2017283878-A1 优先权日:2015-12-11 标题:Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers 发明人:WONG CHI-HUEY; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI; HSU TSUI-LING 权利人:ACADEMIA SINICA 摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for diagnostic and therapeutic uses.
1: Nojkov B, Signori C, Konda A, Fontana RJ. Lenalidomide-associated hepatotoxicity--a case report and literature review. Anticancer Res. 2012 Sep;32(9):4117-9. Review. doi: 10.1007/s11899-012-0133-2. Review. doi: 10.1517/17425255.2012.712685. Epub 2012 Aug 3. Review. Review. doi: 10.1016/j.beha.2012.04.005. Epub 2012 May 18. Review. doi: 10.1016/j.ctrv.2012.02.009. Epub 2012 May 18. Review. doi: 10.1007/s00280-012-1874-2. Epub 2012 May 15. Review. Epub 2012 Apr 29. Review. Review. doi: 10.1007/s00277-012-1445-y. Epub 2012 Apr 4. Review.
合成参考文献
参考文献:10.1007/s12094-010-0474-z 摘要:Gutiérrez-Gutiérrez G, Sereno M, Miralles A, Casado-Sáenz E, Gutiérrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clinical and Translational Oncology. 2010 Feb 20;12(2):81–91. doi: 10.1007/s12094-010-0474-z. 参考文献:10.1007/s00005-010-0070-5 摘要:Zdzisińska B, Bojarska-Junak A, Walter-Croneck A, Kandefer-Szerszeń M. Dysregulation of the Receptor Activator of NF-κB Ligand and Osteoprotegerin Production Influence the Apoptosis of Multiple Myeloma Patients’ Bone Marrow Stromal Cells Co-Cultured with Myeloma Cells. Archivum Immunologiae et Therapiae Experimentalis. 2010 Feb 16;58(2):153–63. doi: 10.1007/s00005-010-0070-5. 参考文献:10.1186/2047-783x-15-1-13 摘要:Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R. Bendamustine in patients with relapsed or refractory multiple myeloma. European Journal of Medical Research. 2010 Jan 29;15(1):13. doi: 10.1186/2047-783x-15-1-13. 参考文献:10.1038/leu.2011.126 摘要:Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia. 2011 Oct;25(10):1620–6. 参考文献:10.1002/pros.21449 摘要:Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate. 2012 Apr;72(5):487–98.